Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Urology, Shunde People's Hospital, Southern Medical University, Guangdong, China.
Urology. 2011 Jul 7.
To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity.
Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to evaluate the antitumor efficiency of the vaccine. Immunohistochemistry, flow cytometric, and cytotoxic T-lymphocyte assay were performed to assess the proportion and cytotoxicity of the T lymphocytes.
The IL-2 surface-modified MB49 cell vaccine inhibited tumor growth and extended the survival of the mice, and the vaccine-cured mice effectively resisted the second MB49 but not the RM-1 prostate cancer cell challenge. Furthermore, more cytotoxicity on the MB49 cells and more CD4-positive, CD8-positive T cells appeared in the vaccine-treated group.
The results of our study have demonstrated that the human interleukin-2 surface-modified MB49 bladder cancer cell vaccine induced specific antitumor immunity and was efficient against metastatic bladder cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.
PMID: 21741685 [PubMed - as supplied by publisher] Source: National Library of Medicine.
